Ali MS, Sayeski PP, Dirksen LB, et al. (1997) Dependence on the motif YIPP for the physical association of jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor. J Biol Chem 272: 23382–23388.
Angers S, Salahpour A, Bouvier M. (2002) Dimerization: an emerging concept for G protein–coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 42: 409–435.
Arch JR (2004) Do low-affinity states of beta-adrenoceptors have roles in physiology and medicine? Br J Pharmacol. 143: 517–518.
Baker JG (2005) Site of action of beta-ligands at the human beta1-adrenoceptor. J Pharmacol Exp Ther 13: 1163–1171.
Berg KA, Maayani S, Goldfarb J, et al. (1998) Effector pathway–dependent relative efficacy at serotonin type 2a and 2c receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54: 94–104.
Birdsall NJM, Hulme EC, Stockton JM (1983) Muscarinic receptor subclasses: allosteric interactions. Cold Spring Harb Symp Quant Biol 48: 53–56.
Birdsall NJM, Lazareno S (2005) Allosterism at muscarinic receptors: ligands and mechanisms. Mini-Rev Med Chem 5: 523–543.
Bockaert J, Marin P, Dumuis A, et al. (2003) The ‘magic tail’ of G protein–coupled receptors: an anchorage for functional protein networks. FEBS Lett 546: 65–72.
Brady AE, Limbird LE (2002) G protein–coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell Signal 14: 297–309.
Chadwick W, Magnus T, Martin B, et al. (2008) Targeting TNF-alpha receptors for neurotherapeutics. Trends Neurosci 31: 504–511.
Christopoulos A, Kenakin T (2002) G protein–coupled receptor allosterism and complexing. Pharmacol Rev 54: 323–374.
Christopoulos A, May LT, Avlani VA, et al. (2004) G-protein–coupled receptor allosterism: the promise and the problem(s). Biochem Soc Trans 32(Pt 5): 873–877.
Daaka Y, Luttrell LM, Lefkowitz RJ (1997) Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A. Nature 390: 88–91.
DeLean A, Stadel JM, Lefkowitz RJ (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase–coupled beta-adrenergic receptor. J Biol Chem 255: 7108–7117.
Franco R, Ferre S, Agnati L, et al. (2000) Evidence for adenosine/dopamine receptor interactions: indications for heteromerization. Neuropsychopharmacology 23: S50–S59.
Fredriksson R, Schiöth HB (2005) The repertoire of G-protein–coupled receptors in fully sequenced genomes. Mol Pharmacol 67: 1414–1425.
George SR, Fan T, Xie Z, et al. (2000) Oligomerization of μ- and δ-opioid receptors. Generation of novel functional properties. J Biol Chem 275: 26128–26135.
Granneman JG (2001) The putative β4-adrenergic receptor is a novel state of the β1-adrenergic receptor. Am J Physiol Endocrinol Metab 280: E199–E202.
Guo W, Shi L, Filizola M, et al. (2005) Crosstalk in G protein–coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci USA 102: 17495–17500.
Holloway AC, Qian H, Pipolo L, et al. (2002) Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1a angiotensin receptors. Mol Pharmacol 61: 768–777.
Jones KA, Borowsky B, Tamm JA, et al. (1998) GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 396: 674–679.
Jordan BA, Devi LA (1999) G-protein–coupled receptor heterodimerization modulates receptor function. Nature 399: 697–700.
Keith DE, Murray SR, Zaki PA, et al. (1996) Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271: 19021–19024.
Kenakin T (2002) Drug efficacy at G protein–coupled receptors. Ann Rev Pharmacol Toxicol 42: 349–379.
Kenakin T (2003) Ligand-selective receptor conformations revisited. The promise and the problem. Trends Pharmacol Sci 24: 346–354.
Kohout TA, Nicholas SL, Perry SJ, et al. (2004) Differential desensitization, receptor phosphorylation, β-arrestin recruitment and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem 279: 23214–23222.
Konkar AA (2000) Aryloxypropanolamine and catecholamine ligand interactions with the β1 adrenergic receptor: evidence for interaction with distinct conformations of β1-adrenergic receptors. J Pharmacol Exp Ther 294: 923–932.
Lazareno S (2004) Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol 65: 257–266.
Laporte SA, Oakley RH, Zhang J, et al. (1999) The beta2-adrenergic receptor/beta arrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci USA 96: 3712–3717.
Liang Y, Fotiadis D, Filipek S, et al. (2003) Organization of the G protein–coupled receptors rhodopsin and opsin in native membranes. J Biol Chem 278: 21655–21662.
Lowe MD (2002) Comparison of the affinity of β-blockers for the two states of the β1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol 135: 451–461.
Luttrell LM, Ferguson SSG, Daaka Y et al. (1999) □-Arrestin–dependent formation of β2 adrenergic receptor/src protein kinase complexes. Science 283: 655–661.
Marlo JE, Niswender CM, Days EL, et al. 2008 Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol Dec 1 [Epub ahead of print].
Maudsley S, Gent JP, Findlay JB, et al. (1998) The relationship between the agonist-induced activation and desensitization of the human tachykinin NK2 receptor expressed in Xenopus oocytes. Br J Pharmacol 124: 675–684.
Maudsley S, Pierce KL, Zamah AM, et al. (2000) The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 275: 9572–9580.
Maudsley S, Zamah AM, Rahman N, Blitzer JT, Luttrell LM, Lefkowitz RJ, Hall RA (2000a) Platelet-derived growth factor receptor association with Na(+)/H(+) exchanger regulatory factor potentiates receptor activity. Mol Cell Biol 20: 8352–8363.
Maudsley S, Davidson L, Pawson AJ, et al. (2004) Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a galphai-coupling state of the type I GnRH receptor. Cancer Res 64: 7533–7544.
Maudsley S, Martin B, Luttrell LM (2005) The origins of diversity and specicity in G protein coupled receptor signaling. J Pharmacol Exp Ther 314: 485–494.
Maudsley S, Martin B, Luttrell LM (2007b) G protein–coupled receptor signaling complexity in neuronal tissue: implications for novel therapeutics. Curr Alzheimer Res 4: 3–19.
Maudsley S, Naor Z, Bonfil D, et al. (2007a) Proline-rich tyrosine kinase 2 mediates gonadotropin-releasing hormone signaling to a specific extracellularly regulated kinase-sensitive transcriptional locus in the luteinizing hormone beta-subunit gene. Mol Endocrinol 21: 1216–1233.
May LT, Leach K, Sexton PA, et al. (2007) Allosteric modulation of g protein–coupled receptors ann. Rev Pharmacol Toxicol 47: 1–51.
Moolenaar P (2003) The ‘state’ of β-adrenoceptors. Br J Pharmacol 140: 1–2.
Pak MD, Fishman PH (1996) Anomalous behavior of CGP 12177a on β1-adrenergic receptors. J Recept Signal Transduct Res 16: 1–23.
Peroutka SJ, Snyder SH (1980) Regulation of serotonin2 (5-HT2) receptors labeled with [3H]spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther 215: 582–587.
Pommier B, Da Nascimento S, Dumont S, et al. (1999) The cholecystokinin B receptor is coupled to two effector pathways through pertussis toxin–sensitive and –insensitive G proteins. J Neurochem 73: 281–288.
Rimoldi V, Reversi A, Taverna E, et al. (2003) Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains. Oncogene 22: 6054–6060.
Roettger BF, Ghanekar D, Rao R, Toledo C, Yingling J, Pinon D,, Miller LJ (1997) Antagonist-stimulated internalization of the G protein–coupled cholecystokinin receptor. Mol Pharmacol 51: 357–362.
Sagan S, Karoyan P, Chassaing G, et al. (1996) Tachykinin peptides affect differently the second messenger pathways after binding to CHO-expressed human NK-1 receptors. J Pharmacol Exp Ther 276: 1039–1048.
Samama P, Cotecchia S, Costa T, et al. (1993) A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268: 4625–4636.
Sexton PM, Albiston A, Morfis M, et al. (2001) Receptor activity modifying proteins. Cell Signal 13: 73–83.
Sneddon WB, Syme CA, Bisello A, et al. (2003) Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50). J Biol Chem 278: 43787–43796.
Soudijn W (2004) Allosteric modulation of G protein–coupled receptors: perspective and recent developments. Drug Discov Today 9: 752–758.
Stout BD, Clarke WP (2002) Berg KA rapid desensitization of the serotonin(2c) receptor system: effector pathway and agonist dependence. J Pharmacol Exp Ther 302: 957–962.
Takeda S, Kadowaki S, Haga T, et al. (2002) Identification of G protein–coupled receptor genes from the human genome sequence. FEBS Lett 520: 97–101.
Tang Y, Hu LA, Miller WE, et al. (1999) Identification of the endophilins (SH3p4/p8/p13) as novel binding partners for the beta1-adrenergic receptor. Proc Natl Acad Sci USA 96: 12559–12564.
Urban JD, Clarke WP, von Zastrow M, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1–13.
van Hooft JA, Vijverberg HP (1996) Selection of distinct conformational states of the 5-HT3 receptor by full and partial agonists. Br J Pharmacol 117: 839–846.
Waelbroeck M (1994) Identification of drugs competing with d-tubocurarine for an allosteric site on cardiac muscarinic receptors. Mol Pharmacol 46: 685–692.
Wang Q, Zhao J, Brady AE et al (2004) Spinophilin blocks arrestin actions in vitro and in vivo at G protein–coupled receptors. Science 304: 1940–1944.
Watson C (2005) The CCR5 receptor–based mechanism of action of 873140, a potent allosteric non competitive HIV entry inhibitor. Mol Pharmacol 67: 1268–1282.
Yu Y, Zhang L, Yin X, et al. (1996) μ-Opioid receptor phosphorylation, desensitization and ligand efficacy. J Biol Chem 272: 28869–28874.
Zhang SJ, Cheng H, Zhou YY, et al. (2000) Inhibition of spontaneous beta 2-adrenergic activation rescues beta 1-adrenergic contractile response in cardiomyocytes overexpressing beta 2-adrenoceptor. J Biol Chem 275: 21773–21779.